. Accumulation of ssDNA gaps on replicated duplexes upon different genotoxic treatments in human cells. (A) Frequency of molecules containing no ssDNA gaps, one ssDNA gap, or more than one ssDNA gap along replicated duplexes (Fig. 2 C, white arrow) in not treated (NT) U2OS cells and upon the indicated treatments (UV pulse or 1-h treatment). Similar results were obtained in one independent experiment. (B) Graphical distribution of the size of ssDNA gaps along replicated duplexes for the same sets of molecules analyzed in A. The lines show the median of the ssDNA gap size in the specific set of analyzed molecules. Similar results were obtained in one independent experiment. In brackets, the total number of analyzed molecules is given. (C) Graphical distribution of ssDNA length at the junction in untreated RPE-1 cells and upon 25 nM CPT, 200 nM MMC, and 0.5 mM HU treatments. Only molecules with detectable ssDNA stretches are included in the analysis. The lines show the median length of the ssDNA region at the fork in the specific set of analyzed molecules. In brackets, the total number of analyzed molecules is given. (D) Frequency of molecules containing no ssDNA gaps, one ssDNA gap, or more than one ssDNA gap along replicated duplexes (Fig. 2 C , white arrow) in untreated RPE-1 cells and upon the indicated 25 nM CPT, 200 nM MMC, and 0.5 mM HU treatments. In brackets, the total number of analyzed molecules is given. 1-h treatment) . In brackets, the total number of analyzed molecules is given. Similar results were obtained in at least one independent experiment. Figure S4 . Dose-dependent DSB induction and differential activation of the DDR upon different genotoxic treatments in human cells. Immunoblot for ATR (pCHK1) and ATM (pATM and pKAP1) activation and total DDR proteins (ATM, CHK1, and KAP1) in not treated (NT) U2OS cells and upon the indicated treatments (UV pulse or 1-h treatment). RPA32 (RPA) phosphorylation at S4/S8 indicates ATM/DNA-PK activation and is typically used as DSB marker. Total RPA32 levels (and phosphorylation-associated mobility shift) are also displayed. DSB formation is also physically assessed by PFGE. 1 µM CPT treatment is used as positive control for DSB induction and full DDR activation. TFIIH is used as a loading control. Similar results were obtained in at least one independent experiment. Figure S5 . ssDNA accumulation and checkpoint activation in unperturbed RECQ1-depleted cells, labeling schemes for iPOND experiments and cell cycle effects of RAD51 depletion. (A) Immunoblot for ATR (pCHK1) and ATM (pATM and pKAP1) activation and total DDR proteins (ATM, CHK1, and KAP1) in U2OS cells stably transduced (shRNA) for Luciferase (shLuc) or RECQ1 depletion (shRECQ1). RPA32 (RPA) phosphorylation at S4/S8 indicates ATM/DNA-PK activation and is typically used as DSB marker. Total RPA32 levels (and phosphorylation-associated mobility shift) are also displayed. 1 µM CPT treatment is used as positive control for full DDR activation. TFIIH is used as a loading control. (B) Frequency of molecules containing no ssDNA gaps, one ssDNA gap, or more than one ssDNA gap along replicated duplexes (Fig. 2 C , white arrow) in U2OS cells stably transfected (shRNA) for Luciferase or RECQ1 depletion. In brackets, the total number of analyzed molecules is given. Similar results were obtained in at least one independent experiment. (C) Labeling scheme for the iPOND experiment in Fig. 6 B. HEK293T cells were labeled with EdU for 7 or 15 min followed by a chase into thymidine (Thy), 0. In brackets, the total number of analyzed molecules is given. Above each column, the percentage of reversed forks is indicated. RECQ1 and RAD51 levels after shRNA-or siRNA-mediated depletion were detected by immunoblotting. GAPDH was used as a loading control.
